𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver transplantation for hepatocellular carcinoma: The MELD impact

✍ Scribed by Pratima Sharma; Vijayan Balan; Jose L. Hernandez; Ann M. Harper; Erick B. Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E. Vargas; David Mulligan; Jorge Rakela; Russell H. Wiesner


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
84 KB
Volume
10
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


The new allocation policy of the United Network of Organ Sharing (UNOS) based on the model for end-stage liver disease (MELD) gives candidates with stage T1 or stage T2 hepatocellular carcinoma (HCC) a priority MELD score beyond their degree of hepatic decompensation. The aim of this study was to determine the impact of the new allocation policy on HCC candidates before and after the institution of MELD. The UNOS database was reviewed for all HCC candidates listed between July 1999 and July 2002. The candidates were grouped by two time periods, based on the date of implementation of new allocation policy of February 27, 2002. Pre-MELD candidates were listed for deceased donor liver transplantation (DDLT) before February 27,2002, and post-MELD candidates were listed after February 27, 2002. Candidates were compared by incidence of DDLT, time to DDLT, and dropout rate from the waiting list because of clinical deterioration or death, and survival while waiting and after DDLT. Incidence rates calculated for pre-MELD and post-MELD periods were expressed in person years. During the study, 2,074 HCC candidates were listed for DDLT in the UNOS database. The DDLT incidence rate was 0.439 transplant/person years pre-MELD and 1.454 transplant/person years post-MELD (P < 0.001). The time to DDLT was 2.28 years pre-MELD and 0.69 years post-MELD (P < 0.001). The 5-month dropout rate was 16.5% pre-MELD and 8.5% post-MELD (P < 0.001).

The 5-month waiting-list survival was 90.3% pre-MELD and 95.7% post-MELD (P < 0.001). The 5-month survival after DDLT was similar for both time periods. The new allocation policy has led to an increased incidence rate of DDLT in HCC candidates. Furthermore, the 5-month dropout rate has decreased significantly. In addi-


πŸ“œ SIMILAR VOLUMES


Liver transplantation for hepatocellular
✍ Alan P. Venook πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 277 KB πŸ‘ 1 views

Background: Liver transplantation for unresectable hepatocellular carcinoma yields disappointing results. Most cases recur within 2 years, often in the transplanted liver. Methods: A combination of neoadjuvant doxorubicin and orthotopic liver transplantation was used in 20 patients with unresectable

Liver transplantation for hepatocellular
✍ Eric Vibert; Jean-Charles Duclos-VallΓ©e; Maria-Rosa Ghigna; Emir Hoti; Chady Sal πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 204 KB πŸ‘ 1 views

Liver transplantation (LT) has become an accepted therapy for end-stage liver disease in human immunodeficiency virus-positive (HIV+) patients, but the specific results of LT for hepatocellular carcinoma (HCC) are unknown. Between 2003 and 2008, 21 HIV+ patients and 65 HIV- patients with HCC were li

Liver transplantation for non–hepatocell
✍ Gregory J. Gores; Julie K. Heimbach; Charles B. Rosen πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 139 KB

## Key Points 1. Hepatic epithelioid hemangioendothelioma is a rare disease with a variable natural history; current data support liver transplantation for unresectable disease. 2. Anti-vascular endothelial cell growth factor therapy may change the approach to hepatic epithelioid hemangioendotheli

The impact of human immunodeficiency vir
✍ Fabrizio Di Benedetto; Giuseppe Tarantino; Roberto Montalti; Giuseppe D'Amico; S πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 297 KB πŸ‘ 1 views

We read with interest the reviews by Ghouri et al. 1 and Martinez et al. 2 Ghouri et al. analyzed the association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD) and concluded that although a diagnosis of NAFLD should prompt diabetes screening, it is insufficient for co